Novartis secures first-of-a-kind haematology approval
European Pharmaceutical Review
DECEMBER 6, 2023
Therefore, with data showing that iptacopan is an “efficacious oral treatment with a demonstrated safety profile [this] could be practice-changing for physicians and help relieve burdens experienced by people with PNH,” Dr Pullarkat added. Patients avoiding transfusion: The transfusion avoidance rate was 95.2 percent for anti-C5.
Let's personalize your content